Standard health insurance does not cover investigational retinal cell therapy. Patients must self-fund or enrol in clinical trials (which may provide treatment at no cost, though few slots are available). Some wealthy nations (e.g., Switzerland) may cover trial participation through national research budgets.
Cell therapy for macular degeneration remains expensive and largely experimental. Treatment costs range from €6,000 to €15,000+ per eye, reflecting iPSC derivation, long-term cell expansion, quality-control testing, and the technical complexity of subretinal or intravitreal injection. Baseline and follow-up imaging (optical coherence tomography [OCT], visual field testing, electroretinography) adds €2,000–4,000. The condition typically affects both eyes, so bilateral treatment approaches €15,000–30,000.
Sunt un candidat? → · Macular Degeneration & Vision: full overview → · Cost Degenerare Maculară și Vedere → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită